Immodulon, the immuno-oncology company, is pleased to announce the appointment of Dr Jerome Zeldis to the Immodulon Board who has also been offered the position of Chairman of the Scientific Advisory Board. Jerry joins the company from Celgene where he held the position of Chief Medical Officer and CEO of Celgene Global Health. During his tenure the company grew into a leading global biopharmaceutical company and brought 6 drugs to market.

Along with extensive academic experience in the sector, and other companies, he has been a board member of a few start-up biotechnology companies and is currently on the board of the Semorex Corporation, PTC Corporation, Soligenix, Trek Therapeutics, and Metastat. He has published 123 peer-reviewed articles and holds 44 US patents.

Dr. Zeldis added “I am particularly pleased to be joining Immodulon which I see as one of the most exciting biopharmaceutical players in the industry. Immodulon’s portfolio of strong assets have yielded some impressive results to date and I am looking forward to the opportunity of building on these foundations to drive the clinical development of immodulon’s world-class, unique immunotherapy compounds.”